Promise of Neoadjuvant Immunotherapy in Resected Non-small Cell Lung Cancer

Immune checkpoint inhibitor (ICI) has been proven to be a major breakthrough in patients with advanced non-small cell lung cancer. Up to now, neoadjuvant therapy using ICI are rare. However, in the context of cancer immunotherapy, neoadjuvant treatment may offer an extra advantage. In this review, we will disscuss the existing preclinical data and emerging clinical findings in the neoadjuvant setting and its potential mechanism of action. We will also highlight the potential damage and the questions that are required to be answered. 
 DOI: 10.3779/j.issn.1009-3419.2020.01.09
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research

Related Links:

DiscussionThe POPCORN study provides a unique platform for translational research to determine the mechanism of action of a novel proposed combination immunotherapy for cancer.Trial registrationProspectively registered on Australian New Zealand Clinical Trials Registry (ACTRN12618001121257) on 06/07/2018.
Source: Trials - Category: Research Source Type: clinical trials
In this study, we investigated genetic variations in EGFR and their association with the clinical and pathological factors of NSCLC. MATERIAL AND METHODS Clinical cases (331 patients) and The Cancer Genome Atlas (TCGA) cases (1040 patients) were selected and analyzed using the refractory mutation systems cBioPortal and the Tumor Immune Estimation Resource (TIMER). RESULTS EGFR mutation frequencies were 54.4% (180 of 331 patients) and 8.0% (83 of 1040 patients) in the clinical and TCGA cohorts, respectively. EGFR mutations were strongly associated with smoking and pathology (P≤0.05) in the clinical cohort, and with gende...
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
er JR, Housseau F, Hellmann MD, Forde PM, Pardoll DM, Ji H, Smith KN Abstract PURPOSE: Neoadjuvant PD-1 blockade is a promising treatment for resectable non-small cell lung cancer (NSCLC), yet immunological mechanisms contributing to tumor regression and biomarkers of response are unknown. Using paired tumor/blood samples from a phase 2 clinical trial (NCT02259621), we explored whether the peripheral T cell clonotypic dynamics can serve as a biomarker for response to neoadjuvant PD-1 blockade. EXPERIMENTAL DESIGN: T cell receptor (TCR) sequencing was performed on serial peripheral blood, tumor and normal lung...
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
AbstractImmune checkpoint inhibition of programmed-death receptor 1 (PD-1) or its ligand (PD-L1) has become a standard in the treatment of metastatic non-small cell lung cancer, either as monotherapy or in combination. Recently, it could be shown that immunotherapy works as consolidation after chemoradiotherapy in locally advanced disease if the tumours express PD-L1. A significant and meaningful survival benefit for consolidation with durvalumab after chemoradiotherapy compared to chemoradiotherapy alone was observed in the PACIFIC trial. In addition, there is a growing body of evidence that this treatment modality is als...
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
This article summarizes the established and new options in additive systemic treatment and presents the current state of treatment. PMID: 31705281 [PubMed - as supplied by publisher]
Source: Der Chirurg - Category: Surgery Authors: Tags: Chirurg Source Type: research
Source: The Journal of Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Source Type: research
Condition:   Multiple Pulmonary Nodules Intervention:   Drug: Nivolumab Injection Sponsor:   Tongji Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | China Health | Immunotherapy | Lung Cancer | Neoadjuvant Therapy | Non-Small Cell Lung Cancer